One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Generation Bio Co. logo
Generation Bio Co. GBIO
report update icon

Quarterly report 2025-Q3
added 05-16-2026

Generation Bio Co. Income Statement 2024-2011 | GBIO

Annual Income Statement Generation Bio Co.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 179 M 255 M 288 M 952 M - - - - - - - - -

Shares

66.6 M 64.5 M 58.1 M 56.3 M 27.3 M - - - - - - - - -

Historical Prices

- 2.77 4.38 5.12 34.9 - - - - - - - - -

Net Income

-132 M -127 M -137 M -119 M -80.5 M -61.3 M -35.8 M - - - - - - -

Revenue

19.9 M 5.9 M - - - - 36 K - - - - - - -

Operating Income

-142 M -139 M -141 M -119 M -81.1 M - - - - - - - - -

EBITDA

-137 M -133 M -136 M -115 M -77.7 M -60.4 M -36.9 M - - - - - - -

Operating Expenses

162 M 144 M 141 M 119 M 81.1 M 62.3 M 37.3 M - - - - - - -

General and Administrative Expenses

37.8 M 50.8 M 44.5 M 33.9 M 22.6 M 12.2 M 9.18 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement Generation Bio Co.

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

6.74 M 6.7 M 67 M 6.7 M 6.67 M 6.65 M 66.4 M 66.2 M 65.9 M 65.7 M 60.2 M 59.5 M 58.9 M 57.1 M 57 M 57 M 56.6 M 56.3 M 55.4 M 46.3 M 45.5 M 11.8 M 5.5 M 5.27 M 4.87 M 4.56 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-5.52 M -20.9 M -14.8 M - -15.3 M -20.4 M -74.5 M - -28.3 M -31.1 M -32.1 M - -31.3 M -37.9 M -35 M - -31.9 M -30.8 M -25.6 M -24.2 M -20.8 M -17.7 M -17.7 M -16.1 M -61.3 M -61.3 M -14.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

1.59 M 765 K 8.72 M - 7.55 M 4.09 M 4.06 M - 2.15 M 880 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-6.71 M -22.9 M -16.6 M - -17.9 M -23.3 M -77.6 M - -31.4 M -33.9 M -34.9 M - -32.7 M -38.5 M -35.3 M - -31.7 M -30.8 M -25.7 M -24.3 M -21 M -17.8 M -18 M -16.2 M -16.3 M -15.3 M -14.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-5.31 M -21.7 M -15.5 M - -16.7 M -22 M -76.3 M - -30.1 M -32.6 M -33.5 M - -31.3 M -37.3 M -34.1 M - -28.3 M -30.8 M -24.6 M -24.3 M -18.5 M -16.3 M -17.4 M -16.2 M -15.1 M -14.8 M -14.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

8.3 M 23.7 M 25.3 M - 25.4 M 27.4 M 81.7 M - 33.5 M 34.8 M 34.9 M - 32.7 M 38.5 M 35.3 M - 31.7 M 30.8 M 25.7 M 24.3 M 21 M 17.8 M 18 M 16.2 M 16.3 M 15.3 M 14.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

12.2 M 7.67 M 8.83 M - 9.18 M 9.52 M 10.4 M - 11.6 M 13 M 12.9 M - 11.5 M 10.1 M 9.79 M - 9.67 M 8.19 M 6.9 M - 5.66 M 4.31 M 4.64 M - 2.89 M 3.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Generation Bio Co. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BELLUS Health BELLUS Health
BLU
- - $ 2.47 B canadaCanada
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
Marinus Pharmaceuticals Marinus Pharmaceuticals
MRNS
- - $ 29.6 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.03 -5.5 % $ 227 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 8.87 4.48 % $ 779 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
- - $ 300 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
- -8.44 % $ 3.4 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.32 2.33 % $ 26.6 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
GT Biopharma GT Biopharma
GTBP
$ 4.42 -2.64 % $ 24.4 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Omeros Corporation Omeros Corporation
OMER
$ 16.91 -1.11 % $ 1.07 B usaUSA
Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Limited
RDY
$ 14.9 2.58 % $ 12.4 B indiaIndia
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.09 4.75 % $ 256 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 5.24 3.05 % $ 382 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.51 1.0 % $ 197 M israelIsrael
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 4.8 4.35 % $ 40.9 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
$ 65.94 0.41 % $ 5.24 B usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 29.89 5.71 % $ 1.99 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.42 1.36 % $ 5.19 B usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 18.27 3.28 % $ 1.96 B usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 2.41 2.99 % $ 610 M usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 12.27 11.34 % $ 1.7 B usaUSA